

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6978)

APPOINTMENT AND RESIGNATION OF NON-EXECUTIVE DIRECTOR CHANGE OF AUDIT COMMITTEE MEMBER AND APPOINTMENT AND RESIGNATION OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

The Board announces that:

1. Mr. Tao has been appointed as a non-executive Director of the Company with effect from 23 August 2021;
2. Mr. Li has tendered his resignation as a non-executive Director of the Company with effect from 23 August 2021;
3. Mr. Tao has been appointed as a member of the audit committee of the Company with effect from 23 August 2021;
4. Ms. Peng Sujiu, an independent non-executive Director of the Company, ceased to be the member of the audit committee of the Company with effect from 23 August 2021;
5. each of Ms. Yin and Ms. Leung has tendered her resignation as the company secretary of the Company with effect from 23 August 2021 and accordingly, Ms. Leung ceased to be an authorised representative of the Company with effect from the same date; and
6. Mr. Yang has been appointed as the company secretary and an authorised representative of the Company with effect from 23 August 2021.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Immunotech Biopharm Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Tao Ran (陶然) (“**Mr. Tao**”) has been appointed as a non-executive Director of the Company with effect from 23 August 2021.

Mr. Tao, aged 55, graduated from Shanghai Jiao Tong University* (上海交通大學) with a bachelor’s degree in electrical engineering in August 1988. He also obtained a master’s degree in economics at the School of Economics and Management, Beihang University (北京航空航天大學) in March 2001. From November 1993 to July 2003, he served various positions in China Resources National Corporation* (中國華潤總公司), a state-owned enterprise in the People’s Republic of China (the “**PRC**”), namely a deputy section chief and deputy manager. From July 2003 to June 2015, he served various positions at China Resources Textile (Group) Co., Ltd.* (華潤紡織(集團)有限公司), a state-owned enterprise in the PRC that mainly engages in the production, processing and distribution of textiles and clothing, namely as the senior director, manager and senior manager of the Investment Management Department, and deputy general manager. From June 2015 to June 2021, he served various positions at China Resources Pharmaceutical Group Limited, a company listed on the Main Board of the Stock Exchange (stock code 3320) (“**CR Pharma**”) and a substantial shareholder of the Company, namely as the senior director and general manager of the Strategic Development Department. He has been serving as the vice president of CR Pharma since June 2021.

The appointment of Mr. Tao to the office of non-executive Director of the Company is not for a specific term and he is subject to retirement by rotation and re-election in accordance with the articles of association of the Company. Mr. Tao is not entitled to any director’s fee under his appointment letter.

Save as disclosed above, as at the date of this announcement, Mr. Tao (i) has not held any positions with the Company and other members of the Group; (ii) has not held any other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any other major appointments and professional qualifications; and (iv) does not have any other relationship with any directors, senior management or substantial or controlling shareholders of the Company; and (v) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board would like to express its warmest welcome to Mr. Tao.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board hereby announces that Mr. Li Yuezhong (“**Mr. Li**”) has resigned from his position as a non-executive Director of the Company with effect from 23 August 2021. Mr. Li has confirmed that he has no disagreement with the Board and there are no other matters with respect to this resignation that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Li for his valuable contribution to the Company during his tenure of service.

CHANGE OF AUDIT COMMITTEE MEMBER

The Board announces that Mr. Tao has been appointed as a member of the audit committee of the Company with effect from 23 August 2021. Ms. Peng Sujiu, an independent non-executive Director, ceased to be the member of the audit committee with effect from 23 August 2021.

Save as disclosed above, Mr. Tao confirmed that there is no other information required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and there are no other matters in connection with the appointments of Mr. Tao as non-executive Director and a member of audit committee of the Board that need to be brought to the attention of the shareholders of the Company.

APPOINTMENT AND RESIGNATION OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

The Board hereby announces that, each of Ms. Yin Mengyang (“**Ms. Yin**”) and Ms. Leung Shui Bing (“**Ms. Leung**”) has tendered her resignation as the company secretary of the Company with effect from 23 August 2021 and accordingly, Ms. Leung has ceased to be an authorised representative of the Company under Rules 3.05 of the Listing Rules with effect from the same date.

Both Ms. Yin and Ms. Leung confirmed that they have no disagreement with the Board and there is no matter in relation to each of their resignation which needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board also announces that Mr. Yang Ning (“**Mr. Yang**”) has been appointed as the company secretary of the Company and an authorised representative of the Company under Rule 3.05 of the Listing Rules with effect from 23 August 2021. Mr. Yang is the chief financial officer of the Group. He has been a member of CPA Australia since March 2010 and a member of the Chinese Institute of Certified Public Accountants since June 2016. He has almost 15 years of experience in accounting and finance.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Yin and Ms. Leung for their valuable contributions to the Company and its warmest welcome to Mr. Yang on his new appointment.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 23 August 2021

As at the date of this announcement, the Board comprises Mr. Tan Zheng as Chairman and executive Director, Dr. Wang Yu and Mr. Jung Hyun Chul as executive Directors, Mr. Si Xiaobing, Mr. Lu Yuan and Mr. Li Yuezhong as non-executive Directors, and Mr. Wang Yingdian, Mr. Ng Chi Kit and Ms. Peng Sujiu as independent non-executive Directors.